# A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Study · id `cardio:ct-nct02019264` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02019264](<https://clinicaltrials.gov/study/NCT02019264>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02019264

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 14673 participants.

## Technical summary

Registry record NCT02019264. Randomized; double masking; primary purpose treatment. Start 2014-01-24 (actual); primary completion 2018-05-14 (actual). Results posted on 2019-07-16.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 14673 participants (enrolled count; ClinicalTrials.gov record NCT02019264, source copy `cardio:ctgov-nct02019264-2019-07-16`, retrieved 2026-10-26)
- Started: 2014-01-24 (actual) (ClinicalTrials.gov record NCT02019264, source copy `cardio:ctgov-nct02019264-2019-07-16`, retrieved 2026-10-26)
- Primary completion: 2018-05-14 (actual) (ClinicalTrials.gov record NCT02019264, source copy `cardio:ctgov-nct02019264-2019-07-16`, retrieved 2026-10-26)
- Completion: 2018-05-14 (actual) (ClinicalTrials.gov record NCT02019264, source copy `cardio:ctgov-nct02019264-2019-07-16`, retrieved 2026-10-26)
- Results first posted: 2019-07-16 (ClinicalTrials.gov record NCT02019264, source copy `cardio:ctgov-nct02019264-2019-07-16`, retrieved 2026-10-26)
- Countries: United States; Australia; Canada; Chile; Mexico; New Zealand; Poland; Bahamas (ClinicalTrials.gov record NCT02019264, source copy `cardio:ctgov-nct02019264-2019-07-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02019264-2019-07-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
- Acronym: CAMELLIA-TIMI
- Condition: Cardiovascular Disease
- Condition: High Cardiovascular Risk
- Condition: Obesity
- Condition: Overweight
- Condition: Type 2 Diabetes
- Intervention (Drug): Lorcaserin hydrochloride
- Intervention (Drug): Placebo
- Lead sponsor: Eisai Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: The TIMI Study Group
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as a collaborator: The TIMI Study Group (`cardio:org-the-timi-study-group`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients (`cardio:pubmed-30145941`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial (`cardio:pubmed-30293771`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial (`cardio:pubmed-30586726`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: d374e2a1972ac50f454eff27bc9c196e5d3121ca614ad51bc5aebb1eca6b9643
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
